Hospital
Waccamaw Community Hospital
Waccamaw Community Hospital was paid $9.78M by Medicaid between Jan 2018 and Dec 2024, across 223 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 26% of everything it billed.
33Billing provider infoWACCAMAW COMMUNITY HOSPITAL
MURRELLS INLET, SC 29576
MURRELLS INLET, SC 29576
33aNPI1972503910assigned 07/29/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.78M
24GClaims339,915
24DCodes billed223
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#33 of 115
Median peer was paid$2.47M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WARD, ELIZABETH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,193 | $1.20M | |
| 2019 | 53,713 | $1.46M | |
| 2020 | 45,691 | $1.18M | |
| 2021 | 54,232 | $1.73M | |
| 2022 | 58,107 | $1.75M | |
| 2023 | 49,940 | $1.51M | |
| 2024incomplete | 37,039 | $957K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 26% | 20,420 | 16,441 | $2.56M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 8.0% | 3,100 | 2,882 | $779K |
| 80053 | Comprehensive metabolic panel | 6.6% | 21,279 | 18,614 | $648K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 4.4% | 616 | 557 | $432K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.2% | 7,655 | 2,056 | $414K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.7% | 9,690 | 9,117 | $360K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 5,727 | 5,342 | $346K |
| 81025 | 3.1% | 3,596 | 3,378 | $301K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.5% | 10,268 | 9,507 | $249K |
| J3490 | Unclassified drugs | 2.4% | 844 | 729 | $239K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.1% | 2,011 | 1,802 | $205K |
| 87070 | 2.0% | 1,832 | 1,753 | $191K |
211 more codes
| 87081 | 1.6% | 1,016 | $156K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 3,914 | $134K |
| 87400 | 1.3% | 1,446 | $124K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 3,475 | $118K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 4,347 | $117K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 2,660 | $111K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,868 | $108K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 2,328 | $100K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,671 | $96K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,115 | $95K |
| 87481 | <1% | 389 | $89K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,231 | $87K |
| 81003 | <1% | 11,031 | $79K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,610 | $77K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 105 | $69K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 640 | $63K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 310 | $63K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 780 | $60K |
| 76830 | Ultrasound, transvaginal | <1% | 491 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,591 | $44K |
| 99460 | <1% | 512 | $43K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,885 | $42K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 380 | $40K |
| 86850 | <1% | 1,396 | $34K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,296 | $33K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,455 | $31K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,182 | $30K |
| 99285 | Emergency room visit (most serious) | <1% | 3,552 | $30K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 307 | $28K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,473 | $28K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,954 | $27K |
| 80061 | Lipid panel | <1% | 5,548 | $27K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 5,834 | $26K |
| 59025 | Fetal non-stress test | <1% | 177 | $25K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,405 | $24K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 370 | $24K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 289 | $22K |
| 99462 | <1% | 696 | $22K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 251 | $22K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 198 | $21K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $20K |
| 0002A | <1% | 583 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,153 | $19K |
| 84439 | <1% | 3,084 | $18K | |
| 87807 | <1% | 1,448 | $16K | |
| 82728 | <1% | 1,558 | $16K | |
| 82607 | <1% | 1,472 | $16K | |
| 96376 | <1% | 1,380 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 226 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,126 | $15K |
| A9270 | Non-covered item or service | <1% | 8,043 | $15K |
| 87077 | <1% | 1,010 | $14K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,031 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,120 | $14K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,573 | $14K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 171 | $14K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 30 | $13K |
| 86592 | <1% | 491 | $13K | |
| 72110 | <1% | 252 | $13K | |
| 0001A | <1% | 602 | $13K | |
| 87150 | <1% | 281 | $13K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,294 | $13K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,153 | $12K |
| G0378 | Hospital observation service, per hour | <1% | 1,596 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,697 | $11K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,055 | $11K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,459 | $10K |
| 73562 | <1% | 247 | $10K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 45 | $10K |
| 82947 | <1% | 357 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 154 | $9K |
| 74018 | <1% | 334 | $9K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 98 | $9K |
| 84702 | <1% | 835 | $8K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 56 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 65 | $8K |
| 85027 | <1% | 5,374 | $8K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 28 | $7K |
| 85610 | <1% | 4,787 | $7K | |
| 82731 | <1% | 68 | $7K | |
| 97161 | <1% | 544 | $6K | |
| 73630 | <1% | 261 | $6K | |
| 87329 | <1% | 39 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 57 | $5K |
| 83735 | <1% | 4,469 | $5K | |
| 73610 | <1% | 112 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,810 | $5K |
| 82565 | <1% | 41 | $5K | |
| 73030 | <1% | 90 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,497 | $4K |
| 87653 | <1% | 117 | $4K | |
| 0003A | <1% | 118 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 138 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 136 | $4K |
| 76641 | <1% | 53 | $4K | |
| 80081 | <1% | 12 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 273 | $3K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 232 | $3K |
| 72050 | <1% | 31 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 92 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $3K |
| 84112 | <1% | 30 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,162 | $2K |
| 84484 | <1% | 3,747 | $2K | |
| 82042 | <1% | 325 | $2K | |
| 82570 | <1% | 1,069 | $2K | |
| 99480 | Subsequent intensive care, per day, low birth weight infant | <1% | 22 | $2K |
| 86900 | <1% | 1,795 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 970 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 140 | $2K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 23 | $2K |
| 99223 | Prolong inpt eval add15 m | <1% | 14 | $2K |
| 86140 | <1% | 1,381 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 25 | $2K |
| 82105 | <1% | 72 | $1K | |
| 0072A | <1% | 37 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 463 | $1K |
| 83540 | <1% | 1,564 | $1K | |
| 85379 | <1% | 647 | $1K | |
| 83690 | <1% | 3,486 | $1K | |
| 0071A | <1% | 31 | $1K | |
| 87210 | <1% | 217 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 100 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,858 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 114 | $1K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 263 | $1K |
| A4649 | Surgical supply; miscellaneous | <1% | 57 | $998.98 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 14 | $978.34 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,477 | $864.99 |
| 80076 | <1% | 88 | $838.45 | |
| 82950 | <1% | 63 | $801.30 | |
| 86803 | <1% | 507 | $776.26 | |
| 54150 | <1% | 14 | $761.76 | |
| 83001 | <1% | 13 | $647.26 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,309 | $640.36 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,537 | $576.15 |
| 84481 | <1% | 1,605 | $513.92 | |
| 81001 | <1% | 467 | $513.13 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,223 | $496.04 |
| 87430 | <1% | 55 | $447.08 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 16 | $429.88 |
| 80320 | <1% | 281 | $429.88 | |
| 73502 | <1% | 15 | $357.77 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 346 | $335.84 |
| 82550 | <1% | 1,417 | $329.45 | |
| 76000 | <1% | 108 | $326.97 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 385 | $312.96 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 693 | $274.10 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 284 | $267.37 |
| 83615 | <1% | 464 | $225.26 | |
| 73130 | <1% | 13 | $197.90 | |
| 87040 | <1% | 1,214 | $184.63 | |
| 83880 | <1% | 622 | $182.24 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 219 | $180.27 |
| 84100 | <1% | 423 | $178.13 | |
| 73110 | <1% | 17 | $174.24 | |
| 85730 | <1% | 2,398 | $168.66 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $162.50 |
| 83605 | <1% | 1,658 | $108.41 | |
| 86901 | <1% | 1,798 | $92.95 | |
| 80074 | <1% | 13 | $70.88 | |
| 87186 | <1% | 1,342 | $62.37 | |
| 84145 | <1% | 396 | $58.96 | |
| 82247 | <1% | 15 | $53.68 | |
| 82077 | <1% | 208 | $37.48 | |
| 84156 | <1% | 225 | $35.32 | |
| 82746 | <1% | 324 | $35.06 | |
| 85652 | <1% | 1,016 | $31.10 | |
| 84550 | <1% | 413 | $30.04 | |
| 84703 | <1% | 87 | $17.88 | |
| 87205 | <1% | 269 | $10.36 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 217 | $9.68 |
| 82553 | <1% | 15 | $7.99 | |
| 83550 | <1% | 1,457 | $7.20 | |
| 86038 | <1% | 12 | $5.86 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,597 | $3.00 |
| 64635 | 0% | 302 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 69 | $0.00 |
| 94760 | 0% | 305 | $0.00 | |
| 85651 | 0% | 254 | $0.00 | |
| 88342 | 0% | 276 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 278 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 81 | $0.00 |
| 82150 | 0% | 25 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 28 | $0.00 |
| 64494 | 0% | 28 | $0.00 | |
| 87340 | 0% | 61 | $0.00 | |
| 20610 | 0% | 58 | $0.00 | |
| 87147 | 0% | 47 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 66 | $0.00 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 35 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 29 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 16 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 33 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 23 | $0.00 |
| 64483 | 0% | 17 | $0.00 | |
| 64493 | 0% | 21 | $0.00 | |
| 83020 | 0% | 12 | $0.00 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 57 | $0.00 |
| 99152 | 0% | 485 | $0.00 | |
| 64495 | 0% | 27 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 90 | $0.00 |
| 64636 | 0% | 167 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 33 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 154 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 45 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| 84450 | 0% | 29 | $0.00 | |
| 77002 | 0% | 14 | $0.00 | |
| 84460 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWARD, ELIZABETH (EVP & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.